Bli medlem
Bli medlem

Du är här

2016-05-19

Prothena Corporation plc: Prothena to Present Quality of Life Data on AL Amyloidosis at European Hematology Association 21st Congress

DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein
immunotherapies, today announced that data from multiple quality of life
studies in patients with AL amyloidosis will be highlighted at The European
Hematology Association (EHA) 21st Congress to be held June 9-12 in
Copenhagen, Denmark.

"We look forward to sharing these qualitative and quantitative data that
advances the understanding of the impact of AL amyloidosis on patients' lives
at the upcoming EHA congress," commented Dale Schenk, PhD, President and
Chief Executive Officer of Prothena, "Our commitment to the amyloidosis
community involves not only research and development towards the goal of
developing a new therapy indicated for AL amyloidosis, but also a commitment
to understanding the impact of this devastating disease on patients' quality
of life."

Data that highlights a variety of aspects of quality of life in AL
amyloidosis, including the relative burden of AL amyloidosis on
health-related quality of life for patients, the impact of treatment-related
symptoms on treatment compliance, impact on absenteeism, job productivity and
loss, and validity of psychometric properties of the SF-36v2® Health Survey,
will be presented in the following sessions:

(Abstract #P784) The Relative Burden of AL Amyloidosis on Health-related
Quality of Life

* Presenter: Spencer Guthrie, Head of Development Affairs, Prothena
Biosciences Inc.
* Session: Quality of life, palliative care, ethics and health economics 2
* Date and Time: Saturday, June 11, 2016 from 17:30 -19:00 CET
* Location: Poster Area (Hall H)

(Abstract #E1445) Treatment History, Tolerability and Impact on Health-Related
Quality of Life in AL Amyloidosis

* e-Poster presentation

(Abstract #E1458) The Impact of AL Amyloidosis on Absenteeism, Reduced
Productivity and Job Loss

* e-Poster presentation

(Abstract #E1441) Psychometric Validation of the SF-36V2® Health Survey in an
AL Amyloidosis Population

* e-Poster presentation

All e-Posters are available Friday, June 10, 9:30 to Saturday, June 11, 19:00
CET

About AL Amyloidosis

Systemic amyloidoses are a complex group of progressive diseases caused by
tissue deposition of misfolded proteins that result in progressive organ
damage. The most common type, AL amyloidosis or primary amyloidosis, involves
a hematological disorder caused by plasma cells that produce misfolded
immunoglobulin light chain resulting in deposits of abnormal AL protein
(amyloid) in the tissues and organs of individuals with this disease. There
are no approved treatments for AL amyloidosis, and none that directly target
potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder
and it is estimated that about 30,000 to 45,000 patients in the U.S. and
Europe suffer from this disease. Both the causes and origins of AL
amyloidosis remain poorly understood. For more information on AL amyloidosis,
please visit the websites of the Amyloidosis Support Group and the
Amyloidosis Foundation.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology
company seeking to fundamentally change the course of progressive diseases
with its clinical pipeline of novel therapeutic antibodies. Fueled by its
deep scientific understanding built over decades of research in protein
misfolding and cell adhesion - the root causes of many serious or currently
untreatable amyloid and inflammatory diseases - Prothena has advanced several
drug candidates into clinical trials while pursuing discovery of additional
novel therapies. Our clinical pipeline of antibody-based product candidates
targets a number of potential indications including AL amyloidosis (NEOD001),
Parkinson's disease and other related synucleinopathies (PRX002) and
inflammatory diseases including psoriasis (PRX003).

Forward-looking Statements

This press release contains forward-looking statements. These statements
relate to, among other things,
our goal to
develop a new therapy specifically indicated for AL amyloidosis. These
statements are based on estimates, projections and assumptions that may prove
not to be accurate, and actual results could differ materially from those
anticipated due to known and unknown risks, uncertainties and other factors,
including but not limited to the risks, uncertainties and other factors
described in the "Risk Factors" sections of our Annual Report on Form 10-K
filed with the Securities and Exchange Commission (SEC) on February 25, 2016
and our subsequent Quarterly Reports on Form 10-Q filed with the SEC.
Prothena undertakes no obligation to update publicly any forward-looking
statements contained in this press release as a result of new information,
future events or changes in Prothena's expectations.
Contacts:
Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose@prothena.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via Globenewswire

HUG#2014095

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.